|Articles|January 27, 2022
Daily Medication Pearl: Linaclotide (Linzess)
Author(s)Saro Arakelians, PharmD
Linaclotide (Linzess) is indicated for irritable bowel syndrome with constipation and chronic idiopathic constipation.
Advertisement
Indication: Linaclotide (Linzess) is a guanylate cyclase-C agonist indicated in adults for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
Insight:
- Dosing: The recommended dosage in adults for IBS-C is 290 mcg orally once daily. For CIC the recommended dosage 145 mcg orally once daily or 72 mcg orally once daily based on individual presentation or tolerability.
- Dosage forms: Capsules in 72 mcg, 145 mcg, and 290 mcg.
- Adverse events: Most common adverse reactions (≥2%) reported in IBS-C or CIC patients are diarrhea, abdominal pain, flatulence, and abdominal distension.
- Mechanism of action: Linaclotide is structurally related to human guanylin and uroguanylin and functions as a guanylate cyclase-C agonist.
- Manufacturer: AbbVie, Ironwood
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Nufymco, Interchangeable Ranibizumab Biosimilar, for Retinal Diseases
2
Achieving Optimal LDL-C Helps Prevent Neoatherosclerosis, Late Stent Failure in Patients With STEMI
3
FDA Approves Milestone Oral Therapy for Adults With Thalassemia Anemia
4
Orforglipron Shows Strong Weight Maintenance in Phase 3 ATTAIN-MAINTAIN Trial
5